Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. [electronic resource]
Producer: 20110512Description: 579-92 p. digitalISSN:- 1365-2141
- Antibodies, Monoclonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- BH3 Interacting Domain Death Agonist Protein -- metabolism
- Cell Survival -- drug effects
- Dose-Response Relationship, Drug
- Drug Screening Assays, Antitumor
- Humans
- Interleukin-6 -- antagonists & inhibitors
- Melphalan -- administration & dosage
- Multiple Myeloma -- metabolism
- Neoplasm Proteins -- metabolism
- Plasma Cells -- drug effects
- Proto-Oncogene Proteins c-akt -- metabolism
- Signal Transduction -- drug effects
- Tumor Cells, Cultured
- bcl-2 Homologous Antagonist-Killer Protein -- metabolism
- bcl-2-Associated X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.